PRACTICAL ONCOLOGY JOURNAL ›› 2015, Vol. 29 ›› Issue (2): 167-172.doi: 10.11904/j.issn.1002-3070.2015.02.016
• Review • Previous Articles Next Articles
FU Yujiao,LI Zhiwei,ZHANG Yanqiao
Received:
Online:
Published:
Abstract: In recent years,the treatment of malignant tumor has entered the era of individualization and molecular target.Therefore,research and development of new therapeutic targets for cancer patients has become a top priority.A large number of clinical and experimental research found that HGF is produced by mesenchymal cells,which is combined with epithelial cells of specific receptors c-Met to activate the receptor tyrosine activity,promoting the growth,migration and morphological change of a variety of cell,and then to promote the tumor invasion,metastasis and angiogenesis.HGF and its receptor c-Met play an important role in the progression of thyroid cancer,breast cancer,lung cancer,head and neck squamous cell carcinomas,central nervous system tumors and digestive system tumors.HGF/c-Met signaling pathway,as a new targets for a variety of solid tumors,is considered to be the most promising therapeutic targets in recent years,it has also become one of the hot spots of current research.This article will mainly discuss HGF and c-Met receptor′s structure,function,activation mechanism and research progress in a variety of malignant tumor.A large number of clinical and experimental research found that HGF is produced by mesenchymal cells and epithelial cells with a specific receptor combination c-Met and activates the receptor tyrosine activity.
CLC Number:
R734.2
FU Yujiao,LI Zhiwei,ZHANG Yanqiao. Progress of c-Met signaling pathways in a variety of malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 167-172.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2015.02.016
http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2015/V29/I2/167